BR9609780A - Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto - Google Patents

Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto

Info

Publication number
BR9609780A
BR9609780A BR9609780A BR9609780A BR9609780A BR 9609780 A BR9609780 A BR 9609780A BR 9609780 A BR9609780 A BR 9609780A BR 9609780 A BR9609780 A BR 9609780A BR 9609780 A BR9609780 A BR 9609780A
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
treatment
conditions processes
Prior art date
Application number
BR9609780A
Other languages
English (en)
Inventor
Francoise Gellibert
Alain Claude-Marie Daugan
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of BR9609780A publication Critical patent/BR9609780A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR9609780A 1995-07-14 1996-07-11 Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto BR9609780A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9514465.5A GB9514465D0 (en) 1995-07-14 1995-07-14 Chemical compounds
PCT/EP1996/003025 WO1997003985A1 (en) 1995-07-14 1996-07-11 Cyclic gmp-specific phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
BR9609780A true BR9609780A (pt) 1999-03-09

Family

ID=10777696

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609780A BR9609780A (pt) 1995-07-14 1996-07-11 Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto

Country Status (24)

Country Link
US (1) US5981527A (pt)
EP (1) EP0846118B1 (pt)
JP (1) JP4150818B2 (pt)
CN (1) CN1069318C (pt)
AR (1) AR003455A1 (pt)
AT (1) ATE216997T1 (pt)
AU (1) AU702324B2 (pt)
BR (1) BR9609780A (pt)
CA (1) CA2226761A1 (pt)
CO (1) CO4700455A1 (pt)
CZ (1) CZ3298A3 (pt)
DE (1) DE69621026T2 (pt)
ES (1) ES2176471T3 (pt)
GB (1) GB9514465D0 (pt)
HR (1) HRP960321B1 (pt)
HU (1) HUP9900006A3 (pt)
IL (1) IL122923A0 (pt)
MX (1) MX9800411A (pt)
NO (1) NO980154L (pt)
PL (1) PL324527A1 (pt)
SK (1) SK3898A3 (pt)
WO (1) WO1997003985A1 (pt)
YU (1) YU42296A (pt)
ZA (1) ZA965934B (pt)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
WO1998058633A2 (en) 1997-06-23 1998-12-30 Queen's University At Kingston Microdose therapy of vascular conditions by no donors
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
ES2187234A1 (es) * 1999-04-30 2003-05-16 Lilly Icos Llc Forma de dosificacion oral para tratar la disfuncion sexual.
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
CA2365782A1 (en) 1999-04-30 2000-11-09 William E. Pullman Treatment of female arousal disorder
EA004872B1 (ru) * 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
US20040152106A1 (en) * 1999-10-07 2004-08-05 Robertson Harold A. Gene necessary for striatal function, uses thereof, and compounds for modulating same
JP2003510349A (ja) * 1999-10-07 2003-03-18 ノヴァ−ニューロン インコーポレーテッド 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物
AP2002002455A0 (en) 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
US20050070499A1 (en) * 1999-11-08 2005-03-31 Pfizer Inc. Compounds for the treatment of female sexual dysfunction
IL139457A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
JP2004500425A (ja) 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
ES2269408T3 (es) * 2000-06-23 2007-04-01 Lilly Icos Llc Inhibidores de fosfodiesterasa especifica de gmp ciclico.
EP1305313A1 (en) * 2000-08-02 2003-05-02 Lilly Icos LLC Fused heterocyclic derivatives as phosphodiesterase inhibitors
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
NZ524572A (en) * 2000-09-06 2004-08-27 Tanabe Seiyaku Co Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ES2248399T3 (es) 2000-10-02 2006-03-16 Lilly Icos Llc Derivados de piridoindol condensado.
WO2002028858A2 (en) * 2000-10-02 2002-04-11 Lilly Icos Llc Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
ATE337320T1 (de) * 2000-11-06 2006-09-15 Lilly Icos Llc Indolderivate als pde5-inhibitoren
MXPA03004023A (es) 2000-11-08 2004-02-12 Lilly Icos Llc Compuestos quimicos.
NZ527585A (en) * 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
MXPA03011080A (es) * 2001-06-05 2004-07-08 Lilly Icos Llc Compuestos tetraciclicos como inhibidores de pde5.
WO2003000691A1 (en) * 2001-06-21 2003-01-03 Lilly Icos Llc Carboline derivatives as pdev inhibitors
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
DE60235198D1 (de) * 2001-12-20 2010-03-11 Merck Serono Sa Coinsins Pyrrolidin-derivatie als prostaglandin-modulatoren
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
AU2003256539B2 (en) * 2002-07-31 2010-03-04 Icos Corporation Modified pictet-spengler reaction and products prepared therefrom
PL1644021T3 (pl) * 2003-06-13 2013-01-31 Ironwood Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
EP1804582A4 (en) * 2004-10-28 2009-12-09 Reddys Lab Ltd Dr POLYMORPH SHAPES OF TADALAFIL
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014055801A1 (en) 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
CN104230960B (zh) * 2013-06-06 2017-02-15 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN104804016B (zh) * 2014-01-23 2017-06-20 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
JP2021507906A (ja) 2017-12-20 2021-02-25 ノバルティス アーゲー 抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
TW202000663A (zh) 2018-02-28 2020-01-01 美商費洛醫療公司 化合物及使用方法
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
EP4684777A1 (en) 2024-07-24 2026-01-28 Adalvo Limited A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino{1',2:1,6]pyrido[3,4-b]indole-1,4-dione

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
IT1217190B (it) * 1988-04-22 1990-03-14 Recordati Chem Pharm Composti utili per il trattamento e diagnosi di disfunzioni frettili
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
DK0459666T3 (da) * 1990-05-31 1994-12-05 Pfizer Lægemidler mod impotens
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds

Also Published As

Publication number Publication date
HUP9900006A3 (en) 1999-11-29
HRP960321B1 (en) 2003-06-30
PL324527A1 (en) 1998-06-08
HRP960321A2 (en) 1998-08-31
GB9514465D0 (en) 1995-09-13
AR003455A1 (es) 1998-08-05
MX9800411A (es) 1998-04-30
CA2226761A1 (en) 1997-02-06
JP4150818B2 (ja) 2008-09-17
DE69621026T2 (de) 2002-08-22
EP0846118B1 (en) 2002-05-02
CO4700455A1 (es) 1998-12-29
CZ3298A3 (cs) 1998-06-17
DE69621026D1 (de) 2002-06-06
SK3898A3 (en) 1998-11-04
NO980154D0 (no) 1998-01-13
JPH11509535A (ja) 1999-08-24
CN1195349A (zh) 1998-10-07
NO980154L (no) 1998-03-10
ZA965934B (en) 1997-02-03
WO1997003985A1 (en) 1997-02-06
AU702324B2 (en) 1999-02-18
ES2176471T3 (es) 2002-12-01
CN1069318C (zh) 2001-08-08
ATE216997T1 (de) 2002-05-15
IL122923A0 (en) 1998-08-16
YU42296A (sh) 1998-12-23
EP0846118A1 (en) 1998-06-10
US5981527A (en) 1999-11-09
AU6419296A (en) 1997-02-18
HUP9900006A2 (hu) 1999-04-28

Similar Documents

Publication Publication Date Title
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9602705A (pt) Composto composição farmacéutica processo para a preparação de um composto e uso
BR9406128A (pt) Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica
BR9503812A (pt) Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto
BR1100850A (pt) Composto, processo para a preparação de um composto, e, composição farmacêutica
BR9604894A (pt) Derivado de acetamida processo para a preparação do mesmo e uma composição farmacêutica contendo o mesmo
BR9609701A (pt) Composição farmacéutica composto e processo para a preparação de compostos
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR9611986A (pt) Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
BR1100323A (pt) Composto, uso de um composto, composição farmacêutica e processo para preparar um composto
BR9407869A (pt) Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
BR9408148A (pt) Processo para tratamento de arritmia composto e formulação farmacêutica
BR9406566A (pt) Composição farmacêutica uso de progesterona e/ou 17 - - estradiol e processo para a fabricação de uma preparação farmacêutica
BR9501770A (pt) Uso de um composto,composto,formulação farmacêutica e processo para preparar um composto
BR9506473A (pt) Composto processo para a preparação de compostos utilização de um composto composição farmacêutica e processo para o tratamento de infecções anti-fúngicas
BR9609467A (pt) Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária
BR9505107A (pt) Composto composiçao farmacêutica processo para a preparaçao de um composto e seu uso
BR9502471A (pt) Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
BR9505610A (pt) Composto composição farmacéutica processo para a preparação de um composto uso e método de tratar inflamação e dor
BR9602150A (pt) Compostos processo para sua preparação processo para a produção de uma formulação farmacêutica formulação farmacêutica e uso
BR9607346A (pt) Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos
BR9610733A (pt) Composto processos para a preparação do mesmo e para o tratamento de um mamífero composição farmacêutica e utilização de um composto
BR9508320A (pt) Processo para a preparação de um composto e cultura biologicamente
BR9610316A (pt) Composto processo para a produção e uso do mesmo processo para o tratamento de doença das vias aéreas e composição farmacêutica

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE PATENTE COM BASE NOS ARTIGOS 8,11 E 13 DA LPI NO 9.279 DE 14/05/1996.

B12B Appeal against refusal [chapter 12.2 patent gazette]